Name | Number of supported studies | Average coverage | |
---|---|---|---|
retinal cone cell | 5 studies | 32% ± 9% | |
macrophage | 5 studies | 19% ± 1% | |
microglial cell | 4 studies | 26% ± 7% | |
non-classical monocyte | 3 studies | 24% ± 7% | |
dendritic cell | 3 studies | 40% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 22% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 491.59 | 1440 / 1445 | 98% | 3.25 | 180 / 183 |
brain | 98% | 363.23 | 2598 / 2642 | 99% | 3.59 | 697 / 705 |
skin | 99% | 684.60 | 1797 / 1809 | 96% | 3.98 | 453 / 472 |
stomach | 99% | 369.21 | 357 / 359 | 95% | 3.12 | 271 / 286 |
intestine | 100% | 507.67 | 966 / 966 | 93% | 2.85 | 490 / 527 |
adrenal gland | 100% | 727.86 | 258 / 258 | 92% | 2.81 | 211 / 230 |
kidney | 100% | 348.54 | 89 / 89 | 89% | 2.51 | 802 / 901 |
breast | 100% | 417.17 | 458 / 459 | 89% | 2.25 | 992 / 1118 |
lung | 100% | 558.31 | 577 / 578 | 88% | 2.16 | 1013 / 1155 |
thymus | 100% | 354.92 | 650 / 653 | 86% | 1.88 | 523 / 605 |
uterus | 95% | 320.27 | 162 / 170 | 88% | 2.22 | 404 / 459 |
bladder | 100% | 499.86 | 21 / 21 | 81% | 2.09 | 410 / 504 |
pancreas | 83% | 152.26 | 272 / 328 | 85% | 2.01 | 151 / 178 |
prostate | 98% | 418.29 | 240 / 245 | 68% | 1.18 | 341 / 502 |
ovary | 61% | 138.39 | 109 / 180 | 76% | 1.79 | 327 / 430 |
liver | 81% | 236.50 | 183 / 226 | 27% | 0.47 | 109 / 406 |
adipose | 100% | 493.29 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 737.33 | 241 / 241 | 0% | 0 | 0 / 0 |
muscle | 99% | 470.01 | 797 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 398.69 | 1319 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 2.87 | 44 / 45 |
heart | 97% | 386.08 | 831 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 3.08 | 27 / 29 |
peripheral blood | 92% | 580.07 | 856 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 86% | 2.33 | 69 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002931 | Biological process | response to ischemia |
GO_0006096 | Biological process | glycolytic process |
GO_0006003 | Biological process | fructose 2,6-bisphosphate metabolic process |
GO_0010332 | Biological process | response to gamma radiation |
GO_0045739 | Biological process | positive regulation of DNA repair |
GO_0019661 | Biological process | glucose catabolic process to lactate via pyruvate |
GO_0006974 | Biological process | DNA damage response |
GO_2000378 | Biological process | negative regulation of reactive oxygen species metabolic process |
GO_0010666 | Biological process | positive regulation of cardiac muscle cell apoptotic process |
GO_1902153 | Biological process | regulation of response to DNA damage checkpoint signaling |
GO_0043069 | Biological process | negative regulation of programmed cell death |
GO_0072593 | Biological process | reactive oxygen species metabolic process |
GO_0045820 | Biological process | negative regulation of glycolytic process |
GO_1903301 | Biological process | positive regulation of hexokinase activity |
GO_1905857 | Biological process | positive regulation of pentose-phosphate shunt |
GO_1901525 | Biological process | negative regulation of mitophagy |
GO_1904024 | Biological process | negative regulation of glucose catabolic process to lactate via pyruvate |
GO_0060576 | Biological process | intestinal epithelial cell development |
GO_0010659 | Biological process | cardiac muscle cell apoptotic process |
GO_0000423 | Biological process | mitophagy |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0071279 | Biological process | cellular response to cobalt ion |
GO_0043456 | Biological process | regulation of pentose-phosphate shunt |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0005634 | Cellular component | nucleus |
GO_0004331 | Molecular function | fructose-2,6-bisphosphate 2-phosphatase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TIGAR |
Protein name | Chromosome 12 open reading frame 5, isoform CRA_b (TP53 induced glycolysis regulatory phosphatase) Fructose-2,6-bisphosphatase TIGAR (EC 3.1.3.46) (TP53-induced glycolysis and apoptosis regulator) (TP53-induced glycolysis regulatory phosphatase) |
Synonyms | hCG_24961 C12orf5 |
Description | FUNCTION: Fructose-bisphosphatase hydrolyzing fructose-2,6-bisphosphate as well as fructose-1,6-bisphosphate . Acts as a negative regulator of glycolysis by lowering intracellular levels of fructose-2,6-bisphosphate in a p53/TP53-dependent manner, resulting in the pentose phosphate pathway (PPP) activation and NADPH production . Contributes to the generation of reduced glutathione to cause a decrease in intracellular reactive oxygen species (ROS) content, correlating with its ability to protect cells from oxidative or metabolic stress-induced cell death . Plays a role in promoting protection against cell death during hypoxia by decreasing mitochondria ROS levels in a HK2-dependent manner through a mechanism that is independent of its fructose-bisphosphatase activity . In response to cardiac damage stress, mediates p53-induced inhibition of myocyte mitophagy through ROS levels reduction and the subsequent inactivation of BNIP3. Reduced mitophagy results in an enhanced apoptotic myocyte cell death, and exacerbates cardiac damage (By similarity). Plays a role in adult intestinal regeneration; contributes to the growth, proliferation and survival of intestinal crypts following tissue ablation . Plays a neuroprotective role against ischemic brain damage by enhancing PPP flux and preserving mitochondria functions (By similarity). Protects glioma cells from hypoxia- and ROS-induced cell death by inhibiting glycolysis and activating mitochondrial energy metabolism and oxygen consumption in a TKTL1-dependent and p53/TP53-independent manner . Plays a role in cancer cell survival by promoting DNA repair through activating PPP flux in a CDK5-ATM-dependent signaling pathway during hypoxia and/or genome stress-induced DNA damage responses . Involved in intestinal tumor progression . . |
Accessions | A0A0U1RQD1 ENST00000179259.6 ENST00000635110.1 Q9NQ88 |